Regarding the possibility of exploiting NCRs in anti-tumor approaches, it must be considered that NKp46 and NKp30 expression is down-regulated in NK cells derived from patients with different types of both hematological and non-hematological cancers (93, 109–116). Here, NCR3 is linked to neoplasm.